These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15705325)

  • 1. HEPA/vaccine plan for indoor anthrax remediation.
    Wein LM; Liu Y; Leighton TJ
    Emerg Infect Dis; 2005 Jan; 11(1):69-76. PubMed ID: 15705325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines and bioterrorism: smallpox and anthrax.
    Kimmel SR; Mahoney MC; Zimmerman RK
    J Fam Pract; 2003 Jan; 52(1 Suppl):S56-61. PubMed ID: 12556279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responding to the threat of bioterrorism: a microbial ecology perspective--the case of anthrax.
    Atlas RM
    Int Microbiol; 2002 Dec; 5(4):161-7. PubMed ID: 12497181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of stand alone air cleaners for shelter-in-place.
    Ward M; Siegel JA; Corsi RL
    Indoor Air; 2005 Apr; 15(2):127-34. PubMed ID: 15737155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthrax vaccines: present status and future prospects.
    Kaur M; Singh S; Bhatnagar R
    Expert Rev Vaccines; 2013 Aug; 12(8):955-70. PubMed ID: 23984963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(45):1024-6. PubMed ID: 12458919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responding to biological incidents--what are the current issues in remediation of the contaminated environment?
    Pottage T; Goode E; Wyke S; Bennett AM
    Environ Int; 2014 Nov; 72():133-9. PubMed ID: 24530001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health response to an anthrax attack: an evaluation of vaccination policy options.
    Baccam P; Boechler M
    Biosecur Bioterror; 2007 Mar; 5(1):26-34. PubMed ID: 17437349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.
    Tierney BC; Martin SW; Franzke LH; Marano N; Reissman DB; Louchart RD; Goff JA; Rosenstein NE; Sever JL; McNeil MM;
    Clin Infect Dis; 2003 Oct; 37(7):905-11. PubMed ID: 13130401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines: countering anthrax: vaccines and immunoglobulins.
    Grabenstein JD
    Clin Infect Dis; 2008 Jan; 46(1):129-36. PubMed ID: 18171228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis against anthrax.
    Splino M; Patocka J
    Acta Medica (Hradec Kralove); 2002; 45(3):85-8. PubMed ID: 12515043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Learning from the 2001 anthrax attacks: immunological characteristics.
    Hadler JL
    J Infect Dis; 2007 Jan; 195(2):163-4. PubMed ID: 17191158
    [No Abstract]   [Full Text] [Related]  

  • 15. An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001.
    Blank S; Moskin LC; Zucker JR
    Emerg Infect Dis; 2003 Jun; 9(6):615-22. PubMed ID: 12780998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparedness for an anthrax attack.
    Franz DR
    Mol Aspects Med; 2009 Dec; 30(6):503-10. PubMed ID: 19619577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalational anthrax.
    JAMA; 2002 Feb; 287(5):579. PubMed ID: 11838446
    [No Abstract]   [Full Text] [Related]  

  • 18. [Selected research problems of anthrax vaccine development].
    Zakowska D; Kocik J; Bartoszcze M
    Przegl Epidemiol; 2009; 63(4):505-12. PubMed ID: 20120948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center.
    Sanderson WT; Stoddard RR; Echt AS; Piacitelli CA; Kim D; Horan J; Davies MM; McCleery RE; Muller P; Schnorr TM; Ward EM; Hales TR
    J Appl Microbiol; 2004; 96(5):1048-56. PubMed ID: 15078521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pakistan's experience of a bioterrorism-related anthrax scare.
    Ahmad K; Dil AS; Kazi BM; Us-Saba N; Ansari J; Nomani K
    East Mediterr Health J; 2004; 10(1-2):19-26. PubMed ID: 16201705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.